Bone mineral abnormalities (defined as Chronic Kidney Disease Mineral Bone Disorder; CKD-MBD) are prevalent and associated with a substantial risk burden and poor prognosis in CKD population. Several lines of evidence support the notion that a large proportion of patients receiving maintenance dialysis experience a suboptimal biochemical control of CKD-MBD. Although no study has ever demonstrated conclusively that CKD-MBD control is associated with improved survival, an expanding therapeutic armamentarium is available to correct bone mineral abnormalities. In this position paper of Lombardy Nephrologists, a summary of the state of art of CKD-MBD as well as a summary of the unmet clinical needs will be provided. Furthermore, this position paper will focus on the potential and drawbacks of a new injectable calcimimetic, etelcalcetide, a drug available in Italy since few months ago.
|Titolo:||Nuovi scenari nell’iperparatiroidismo secondario: etelcalcetide : Position Paper dei Nefrologi lombardi [New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy]|
COZZOLINO, MARIO GENNARO (Secondo)
MESSA, PIERGIORGIO (Penultimo) (Corresponding)
|Parole Chiave:||CKD-MBD; cinacalcet; PTH; etelcalcetide; secondary hyperparathyroidism|
|Settore Scientifico Disciplinare:||Settore MED/14 - Nefrologia|
|Data di pubblicazione:||mag-2018|
|Appare nelle tipologie:||01 - Articolo su periodico|